发布求助
文献互助 智能选刊 最新文献

Cancer chemotherapy reports最新文献

筛选
英文 中文
5-day iv infusion with 5-fluorouracil (5-FU; NSC-19893) for gastroenteric carcinoma after failure on weekly 5-FU therapy. 5-氟尿嘧啶静脉滴注5天(5-FU;NSC-19893)在每周5-FU治疗失败后的胃肠道癌。
Cancer chemotherapy reports Pub Date : 1975-11-01
G J Hum, J R Bateman
{"title":"5-day iv infusion with 5-fluorouracil (5-FU; NSC-19893) for gastroenteric carcinoma after failure on weekly 5-FU therapy.","authors":"G J Hum, J R Bateman","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 6","pages":"1171-9"},"PeriodicalIF":0.0,"publicationDate":"1975-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"11967109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase I-II clinical trial with mitoclomine (NSC-114575) in chronic lymphocytic leukemia. 米托氯胺(NSC-114575)治疗慢性淋巴细胞白血病的I-II期临床试验。
Cancer chemotherapy reports Pub Date : 1975-11-01
E Longeval, D Ganglji, P Stryckmans, Y Kenis
{"title":"Phase I-II clinical trial with mitoclomine (NSC-114575) in chronic lymphocytic leukemia.","authors":"E Longeval, D Ganglji, P Stryckmans, Y Kenis","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 6","pages":"1173-5"},"PeriodicalIF":0.0,"publicationDate":"1975-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"11967956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Laminar air flow room reverse isolation and microbial suppression to prevent infection in patients with cancer. 层流室反向隔离和微生物抑制预防癌症患者感染。
Cancer chemotherapy reports Pub Date : 1975-11-01
S C Schimpff
{"title":"Laminar air flow room reverse isolation and microbial suppression to prevent infection in patients with cancer.","authors":"S C Schimpff","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 6","pages":"1055-60"},"PeriodicalIF":0.0,"publicationDate":"1975-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12003723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tissue disposition of 3H-actinomycin D (NSC-3053) in the rat, monkey, and dog. 3h -放线菌素D (NSC-3053)在大鼠、猴子和狗体内的组织分布。
Cancer chemotherapy reports Pub Date : 1975-11-01
W M Galbraith, L B Mellett
{"title":"Tissue disposition of 3H-actinomycin D (NSC-3053) in the rat, monkey, and dog.","authors":"W M Galbraith,&nbsp;L B Mellett","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Tissue concentration of 3H-actinomycin D have been determined in the rat, monkey, and dog after an iv dose of 0.6 mg/m2 body surface area. The drug-tissue half-life was determined for various tissues of the rat, monkey, and dog. A mean drug-tissue half-life of 47 hours was calculated for the tissues of the dog. Exceptions were the testis and brain. Significant concentrations of 3H-actinomycin D failed to accumulate in the brain. Although testis drug concentrations were lower than most other tissues evaluated, the drug-tissue half-life was significantly greater than that of other tissues. In all species studied 3H-actinomycin D was rapidly depleted from serum after iv dosage, with concomitant accumulation of drug in the tissues. 3H-actinomycin D was excreted via the biliary and urinary routes in all species studied. No metabolites of 3H-actinomycin D were detected in the bile or urine of the rat, monkey, or dog with the methods employed. When expressed on a body weight basis, body surface area doses were more than threefold greater in the rat than in the dog. However, the average ratio of concentration X time values (rat C X T/dog C X T) for 11 different tissues of the rat and dog was only 1.3. The results strongly suggest that an equivalent dose of actinomycin D, with dosage based on a body surface area basis, results in nearly equal tissue-drug exposure for most tissues in various mammalian species.</p>","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 6","pages":"1601-9"},"PeriodicalIF":0.0,"publicationDate":"1975-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12003720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intraoral topical application of 5-fluorouracil (NSC-19893) as a "mouthwash" in the treatment of residual or relapsing cancer of the lip or buccal mucosa. 口腔内局部应用5-氟尿嘧啶(NSC-19893)作为“漱口水”治疗残留或复发的唇或颊粘膜癌。
Cancer chemotherapy reports Pub Date : 1975-11-01
T Umsawasdi, P Sawarnkatata
{"title":"Intraoral topical application of 5-fluorouracil (NSC-19893) as a \"mouthwash\" in the treatment of residual or relapsing cancer of the lip or buccal mucosa.","authors":"T Umsawasdi,&nbsp;P Sawarnkatata","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 6","pages":"1052-3"},"PeriodicalIF":0.0,"publicationDate":"1975-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12398677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cyclophosphamide (NSC-26271) maintenance therapy after a second remission of childhood acute lymphoblastic leukemia: comparative clinical trial (standard dose versus intermittent high dose versus cyclophosphamide plus cytosine arabinoside (NSC-63878)). 儿童急性淋巴细胞白血病第二次缓解后的环磷酰胺(NSC-26271)维持治疗:比较临床试验(标准剂量与间歇性高剂量与环磷酰胺加阿拉伯糖胞嘧啶(NSC-63878))。
Cancer chemotherapy reports Pub Date : 1975-11-01
V Albo, N Movassaghi, A L Sitarz, D Hammond, J Weiner, A Reed
{"title":"Cyclophosphamide (NSC-26271) maintenance therapy after a second remission of childhood acute lymphoblastic leukemia: comparative clinical trial (standard dose versus intermittent high dose versus cyclophosphamide plus cytosine arabinoside (NSC-63878)).","authors":"V Albo,&nbsp;N Movassaghi,&nbsp;A L Sitarz,&nbsp;D Hammond,&nbsp;J Weiner,&nbsp;A Reed","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Children with acute lymphoblastic leukemia who had experienced only one relapse were reinduced into remission using a 6-week induction course of prednisone and vincristine. One hundred fifty-one children who achieved a second complete marrow remission were randomly assigned to one of three cyclophosphamide treatment groups for maintanence. Forty-one children received standard-dose cyclophosphamide (3 mg/kg/day), 55 received intermittent high-dose cyclophosphamide (10 mg/kg/day for 4 days out of 14), and 55 received a combination of oral cyclophosphamide (3 mg/kg/day) plus cytosine arabinoside (3 mg/kg/week im). The standard-dose cyclophosphamide regimen resulted in a remission maintenance time of 109 days and was the least toxic of the three maintenance regimens. Giving cyclophosphamide on an intermittent high-dose schedule or combining it with cytosine arabinoside did not increase the remission maintanence time (105 days).</p>","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 6","pages":"1097-102"},"PeriodicalIF":0.0,"publicationDate":"1975-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"11967096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Guanazole (NSC-1895)--a phase I clinical study. Guanazole (NSC-1895)- I期临床研究。
Cancer chemotherapy reports Pub Date : 1975-11-01
E M Caoili, R W Talley, F Smith, P Salem, V K Vaitkevicius
{"title":"Guanazole (NSC-1895)--a phase I clinical study.","authors":"E M Caoili,&nbsp;R W Talley,&nbsp;F Smith,&nbsp;P Salem,&nbsp;V K Vaitkevicius","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Two dose schedules of guanazole were used in this phase I clinical study: intermittent prolonged 5-day infusion and intermittent iv bolus twice weekly. Ninety-seven treatment observations were analyzed for toxic effects resulting from the prolonged infusion and 42 from the twice-weekly bolus schedule. The main toxic effect was bone marrow suppressions, the frequency and severity of which were intensified by prior chemotherapy or radiotherapy and repetition of guanazole therapy. The leukocyte count was affected more than the platelet count. Partial responses were observed in four patients: two with lung carcinoma, one with prostate carcinoma, and one with melanoma. Further phase II clinical studies of guanazole are indicated.</p>","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 6","pages":"1117-21"},"PeriodicalIF":0.0,"publicationDate":"1975-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"11967097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combination vincristine (NSC-67574) and hydroxyurea (NSC-32065) for metastatic renal carcinoma. 长春新碱(NSC-67574)和羟基脲(NSC-32065)联合治疗转移性肾癌。
Cancer chemotherapy reports Pub Date : 1975-11-01
D E Johnson, L Rodriguez, P Y Holoye, M L Samuels
{"title":"Combination vincristine (NSC-67574) and hydroxyurea (NSC-32065) for metastatic renal carcinoma.","authors":"D E Johnson,&nbsp;L Rodriguez,&nbsp;P Y Holoye,&nbsp;M L Samuels","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 6","pages":"1159-60"},"PeriodicalIF":0.0,"publicationDate":"1975-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"11967103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase I study of corynebacterium parvum in patients with solid tumors. 小棒状杆菌在实体瘤患者中的I期研究。
Cancer chemotherapy reports Pub Date : 1975-11-01
P R Band, C Jao-King, R C Urtasun, M Haraphongse
{"title":"Phase I study of corynebacterium parvum in patients with solid tumors.","authors":"P R Band,&nbsp;C Jao-King,&nbsp;R C Urtasun,&nbsp;M Haraphongse","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Nineteen patients with various solid tumors were treated with Corynebacterium parvum for 10 consecutive days at doses ranging from 0.5 to 6 mg/m2. Major toxic effects included rigors and cyanosis, hypertension, headache, nausea, and vomiting. Toxicity was maximal during the first 3 days of treatment and decreased or even disappeared when, on subsequent days, increasing doses of the vaccine were given. Objective tumor regressions were observed in four patients.</p>","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 6","pages":"1139-45"},"PeriodicalIF":0.0,"publicationDate":"1975-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"11967100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Toxicology studies with cytembena (NSC-104801), an antineoplastic agent with a multispecies nephrotoxic effect. 具有多物种肾毒性作用的抗肿瘤药物cytembena (NSC-104801)的毒理学研究。
Cancer chemotherapy reports Pub Date : 1975-11-01
E J Gralla, G L Coleman, G W Osbaldiston, M Kashgarian, A M Jonas
{"title":"Toxicology studies with cytembena (NSC-104801), an antineoplastic agent with a multispecies nephrotoxic effect.","authors":"E J Gralla,&nbsp;G L Coleman,&nbsp;G W Osbaldiston,&nbsp;M Kashgarian,&nbsp;A M Jonas","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The toxic effects of cytembena in beagle dogs and rhesus monkeys were investigated with the drug given as single or daily iv injections in doses ranging from 12.5 to 200 mg/kg/day to dogs and 6.25 to 50 mg/kg/day to monkeys. Renal tubular damage was a major drug- and dose-related finding in both species and was clinically indicated by an accompanying uremia, elevated serum creatinine, and proteinuria. In the kidney, the primary lesion was cellular necrosis and desquamation of the distal tubular epithelium in animals given the lowest toxic doses. More severe but similar histologic changes produced by this drug were further characterized by single dose studies in mice which showed renal mitochondrial swelling and disruption plus generalized cell swelling as progressive, subcellular developments which were well established 24 hours after treatment. Cellular regeneration in the renal tubular epithelium was found in dogs and monkeys retained 6 weeks for observation after treatment, although functional recovery was inconsistent. A toxic effect to lymphoid tissue was an additional finding which is described.</p>","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 6","pages":"1071-81"},"PeriodicalIF":0.0,"publicationDate":"1975-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12003725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信